Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the V 15-32 INTEREST and IPASS trials[J]. Nat Rey Clin Onco, 2009, 6(5): 287-294.
[4]
Sanford M, Scott LJ. Gefitinib a review of its use in the treatm ent of locally advanced/m etastatic non-small cell lung cancer[J]. Drugs, 2009, 69(16): 2303-2328.
[5]
Ebi N, Semba H, Tokunaga SJ, et al. A phase Ⅱ trial of gefitinib monotherapy in chem. Otherapy-nave patients of 75 years or olderw ith advanced non-small cell lung cancer[J]. J Thorac Onco, 2008, 3(10): 1166-1171.
Inoue A, Kobayashi. First-line gefitin ib for patients withadvanced non-snall lung cancer harboring eprdemal grow th factor receptor mutations without indication for chemotherapy[J]. J ClimOncoj, 2009, 27(9): 1350-1354.
[9]
Fischer JR, GeigerD. Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessm ent of the EGF-receptormutation status [J]. Pneumologie, 2007, 61(4): 264-269.
[10]
Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidemalgrow th factor receptor gene mutation in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2007, 2(1): 22-28.
[11]
Varella-Garcia M, Mitsudami T, Yatabe Y, et al. EGFR and HER2 genam ic gain in recurrent non-small cell lung cancer after sungery im pact on outcame to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort [J]. J Thorac Onco, 2009, 4(3): 318-325.
[12]
杨衿记, 吴一龙. 先睹为快[J]. 循证医学, 2009, 8(4): 66.
[13]
Wu YL, Zhong WZ, Li LY, et al. Epiderm al grow th factor receptor mutations and their correlation with grfitinib therapy in patients with non-small cell lung cancer ameta-analysis based on updated individual patient data from six medical centers in mainland China[J]. J Thorac Oncol, 2007, 2(5): 430-439.
